Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aze Wilson

Showing results (31-40 of 41) with videos related to

Pageof 5
Sort By:
Scientific Reports|January 25, 2022
High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonistsAngela Guo, Cameron Ross, Nilesh Chande, et al.
Clinical and Translational Gastroenterology|April 6, 2021
Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort StudyAze Wilson, Qian Wang, Yun-Hee Choi, et al.
Digestive Diseases and Sciences|July 11, 2015
Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel DiseaseAze Wilson, Wendy A Teft, Bridget L Morse, et al.
Pharmacogenetics and Genomics|April 21, 2026
TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel diseaseMohammed Alkhalifa, Gio R Dela Cruz, Terry Ponich, et al.
Digestive Diseases and Sciences|August 3, 2015
Erratum to: Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel DiseaseAze Wilson, Wendy A Teft, Bridget L Morse, et al.
Clinical and Translational Gastroenterology|January 21, 2026
Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-α Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort StudyEryn Rooney, Gio R Dela Cruz, Terry Ponich, et al.
Eclinicalmedicine|March 18, 2024
Propofol sedation does not improve measures of colonoscopy quality but increase cost - findings from a large population-based cohort studySheikh Rahman, Lauren E Cipriano, Cassandra McDonald, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2025
IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-α-Induced Paradoxical Psoriasis in Inflammatory Bowel DiseaseNavneet Natt, Monica Gindi, Gio R Dela Cruz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysisVirginia Solitano, Antonio Facciorusso, Dermot P B McGovern, et al.
JAMA Network Open|August 31, 2022
Association of Trainee Participation in Colonoscopy Procedures With Quality MetricsMichael Sey, Sarah Cocco, Cassandra McDonald, et al.
Pageof 5

Showing results (31-40 of 41) with videos related to

Sort By:
Pageof 5
Scientific Reports|January 25, 2022
High oncostatin M predicts lack of clinical remission for patients with inflammatory bowel disease on tumor necrosis factor α antagonistsAngela Guo, Cameron Ross, Nilesh Chande, et al.
Clinical and Translational Gastroenterology|April 6, 2021
Pretreatment HLADQA1-HLADRB1 Testing for the Prevention of Azathioprine-Induced Pancreatitis in Inflammatory Bowel Disease: A Prospective Cohort StudyAze Wilson, Qian Wang, Yun-Hee Choi, et al.
Digestive Diseases and Sciences|July 11, 2015
Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel DiseaseAze Wilson, Wendy A Teft, Bridget L Morse, et al.
Pharmacogenetics and Genomics|April 21, 2026
TWSG1 variation identifies a ustekinumab-response phenotype in patients with inflammatory bowel diseaseMohammed Alkhalifa, Gio R Dela Cruz, Terry Ponich, et al.
Digestive Diseases and Sciences|August 3, 2015
Erratum to: Trimethylamine-N-oxide: A Novel Biomarker for the Identification of Inflammatory Bowel DiseaseAze Wilson, Wendy A Teft, Bridget L Morse, et al.
Clinical and Translational Gastroenterology|January 21, 2026
Combining Cytokine-Related Biomarkers to Better Define Tumor Necrosis Factor-α Antagonist Response in Inflammatory Bowel Disease: An Observational Cohort StudyEryn Rooney, Gio R Dela Cruz, Terry Ponich, et al.
Eclinicalmedicine|March 18, 2024
Propofol sedation does not improve measures of colonoscopy quality but increase cost - findings from a large population-based cohort studySheikh Rahman, Lauren E Cipriano, Cassandra McDonald, et al.
Alimentary Pharmacology & Therapeutics|September 17, 2025
IL23 Receptor Polymorphism Is a Predictor of Anti-Tumour Necrosis Factor-α-Induced Paradoxical Psoriasis in Inflammatory Bowel DiseaseNavneet Natt, Monica Gindi, Gio R Dela Cruz, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 15, 2023
HLA-DQA1∗05 Genotype and Immunogenicity to Tumor Necrosis Factor-α Antagonists: A Systematic Review and Meta-analysisVirginia Solitano, Antonio Facciorusso, Dermot P B McGovern, et al.
JAMA Network Open|August 31, 2022
Association of Trainee Participation in Colonoscopy Procedures With Quality MetricsMichael Sey, Sarah Cocco, Cassandra McDonald, et al.
Pageof 5